aTyr Pharma, Inc. Share Price & Technical Analysis
ATYR · $0.48 (-2.04%)
Healthcare / Biotechnology
$0.48
-2.04%
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-37% return in May, 17% avg return in past 3 year May month.
-25% return in 2026, 20% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 13% | 11% | -11% | 0% | -37% | – | – | – | – | – | – | – | -25% |
| 25 | 5% | 14% | -25% | 17% | 29% | 13% | -8% | 20% | -87% | 29% | -11% | 0% | -4% |
| 24 | 14% | 19% | 5% | -20% | 6% | -11% | 25% | -5% | -5% | 72% | 9% | 0% | 110% |
| 23 | 5% | -9% | 0% | -5% | 15% | -4% | -9% | -15% | -6% | -25% | 0% | 8% | -46% |
| 22 | -20% | -14% | 8% | -25% | -32% | 0% | 25% | -3% | -12% | -17% | -12% | 0% | -100% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$69.16M
P/E ratio
—
52W high
$7.29
52W low
$0.40
Volume
22,74,880
Beta
0.66
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is aTyr Pharma, Inc. share price today?
- aTyr Pharma, Inc. (ATYR) last traded around $0.48 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ATYR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ATYR. Download the app for real-time alerts.
- How can I analyze aTyr Pharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.